Best Life Sciences Platforms and Tools Companies in South Korea
The 201 best Life Sciences Platforms and Tools companies in South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cellid.
Tracking the best Life Sciences Platforms and Tools companies in South Korea by disclosed equity funding and recent momentum, this directory covers 201 companies and $2.8B in total capital raised. The global market sits at roughly $89.4B and is forecast to reach $183.8B by 2027, a 10.8% CAGR driven by advances in quantitative accuracy, mass spectrometry resolution, and information sciences. Cellid towers over the field with $2.4B disclosed, a figure that skews the whole dataset hard. CHA Biotech follows at $68M, then UPPthera at $35M and Rokit Healthcare at $30M. So what does the spread tell you? That capital here concentrates fast, with a handful of platform builders absorbing most of the oxygen.
The active-investor side is worth watching too. Aju IB Investment, Korea Investment Holdings, and IMM Investment keep showing up across rounds, which I'd read as a signal that institutional conviction in this sector is genuinely sticky, not just opportunistic. As shown in 2010 research, foundational genomics tooling has long underpinned platform scalability, and that logic still holds. Regulatory complexity remains a structural friction point for companies moving from tool to clinical application. But the pipeline is real, the funding is moving, and the 201-company count says the ecosystem's still building.
- ResearchAndMarkets.com
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in South Korea
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cellid Developer of personalized vaccines to treat cancer and infectious diseases 32Patents top 32%Funding top 35%Innovation top 40%Moat top 45% All 8 signals ▾Patentstop 32% Fundingtop 35% Innovationtop 40% Moattop 45% Marketbottom 48% Globalbottom 35% Fin. healthbottom 35% Techbottom 22% Patents: 32 patents matched (strict assignee match) · 26 filings since 2022 vs 4 in 2017-21 Funding: Raised $2.4B across 1 rounds · 1 rounds over 12 yrs (0.1/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $2.4B | 120 mo ago | 68 | 2014 | — | PHPNginxNaver Analytics+5 | 32 patents Patents concentrated in chemistry & materials | — |
| 2 | CHA Biotech Developer of stem cell therapeutics 40Funding top 23%News top 31%Partners top 32%Moat top 38% All 11 signals ▾Fundingtop 23% Newstop 31% Partnerstop 32% Moattop 38% Growthtop 42% Patentstop 43% Talentbottom 49% Innovationbottom 46% Techbottom 43% Marketbottom 36% Globalbottom 35% Funding: Raised $67.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) News: 5 BI events in 12 mo (of 12 tracked, 5 types) · +25% YoY rank vs industry peers · Fliar Intelligence Index 40/100 | $68M | 5 mo ago | — | 2000 | Sang Oh CEO | WordPressMySQLPHP+11 | 74 patents Umbilical cord stem cell therapies and NK cell immunotherapies for reproductive and cancer treatments | — |
| 3 | UPPthera Developer of drugs for treating multiple diseases 78Innovation top 22%Patents top 24%Moat top 32%Talent top 35% All 7 signals ▾Innovationtop 22% Patentstop 24% Moattop 32% Talenttop 35% Fundingtop 41% Markettop 43% Globalbottom 35% Innovation: 89 patents (top 32% of patent-holders) · 69 filings since 2022 vs 20 in 2017-21 Patents: 89 patents matched (strict assignee match) · 69 filings since 2022 vs 20 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $35M | 49 mo ago | 63 | 2018 | Hwa Lee Co-Founder & COO | — | 89 patents Design of PROTACs for selective degradation of kinases and metabolic enzymes. | — |
| 4 | ROKIT Healthcare Provider of 4D bio-printer solutions for tissue regenerative 64Patents top 24%Innovation top 26%Tech top 28%Product top 28% All 11 signals ▾Patentstop 24% Innovationtop 26% Techtop 28% Producttop 28% Moattop 29% Fundingtop 33% Growthtop 35% Markettop 50% Talentbottom 49% Fin. healthbottom 43% Globalbottom 42% Patents: 168 patents matched (strict assignee match) · 84 filings since 2022 vs 84 in 2017-21 Innovation: 168 patents (top 10% of patent-holders) · 84 filings since 2022 vs 84 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $30M | 3 mo ago | 65 | 2012 | Seokhwan You Chairman & Ceo | Cart FunctionalityWordPressMySQL+25 | 168 patents Personalized 3D bioprinting of regenerative dermal and cartilage scaffolds for diabetic foot care | 1 partnership |
| 5 | Curiox Developer of wall-less plates and washers for automated cell-based assays | $30M | 51 mo ago | 57 | 2007 | Leck Joo Co-Founder | WordPressBetterDocsMySQL+41 | — | 1 launch · 1 award |
| 6 | Mepsgen Developer of human organ model chips for pharmaceutical development 42Patents top 24%Moat top 32%Funding top 34%Innovation top 35% All 9 signals ▾Patentstop 24% Moattop 32% Fundingtop 34% Innovationtop 35% Growthtop 35% Talentbottom 49% Globalbottom 43% Marketbottom 33% Techbottom 24% Patents: 49 patents matched (strict assignee match) · 47 filings since 2022 vs 2 in 2017-21 Moat: Editorial + unicorn rating 4/10 · IP moat: 49 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $29M | 19 mo ago | 20 | 2019 | Yongtae Kim Co-Founder & CEO | DreamWeaverPHPYouTube+10 | 49 patents Microfluidic fabrication of lipid‑based nanoparticles and HDL mimetics for drug delivery | — |
| 7 | Lemonex Developer of drug delivery technology and biosensor technology | $27M | 61 mo ago | 9 | 2013 | Dal-Hee Min Co-Founder & CTO | — | 181 patents Nanocarrier-based drug and nucleic‑acid delivery systems for antiviral and cancer therapies | — |
| 8 | NEXEL Provider of induced pluripotent stem cell (iPSC)-derived cells and organoids | $27M | 62 mo ago | 22 | 2012 | Choongseong Han CEO | PHPBootstrapNginx+10 | 68 patents Patents concentrated in health & consumer products | — |
| 9 | Advanced Protein Technologies Developer of biomaterials based on recombinant protein production technology | $17M | 55 mo ago | 11 | 2001 | Chul Shin CEO | — | 65 patents Fucosylated oligosaccharide synthesis and therapeutic/functional food applications | — |
| 10 | G + FLAS Life Sciences Developing gene editing technologies for new drugs and plant-based biopharmaceuticals | $12M | 81 mo ago | 9 | 2014 | Sunghwa Choe CEO | — | 88 patents CRISPR-based gene therapies and plant‑derived biologics for targeted cancer treatment | — |
| 11 | Genacast Provider of liquid-biopsy-based cancer detection platform | $12M | 72 mo ago | 27 | 2016 | Seung Chan Baek CEO | — | — | — |
| 12 | LegoChem Biosciences Developer of small molecule drugs | $11M | 117 mo ago | 135 | 2006 | Sejin Park Co-Founder & CFO | — | 349 patents Targeted antibody-drug conjugates and linker‑payload chemistries for oncology therapeutics. | — |
| 13 | Speclipse Provider of molecular spectroscopy systems for early-stage skin cancer detection | $11M | 58 mo ago | 12 | 2015 | — | GnuboardMySQLPHP+11 | 124 patents AI-driven skin cancer imaging diagnostics and point‑of‑care analyte measurement devices | — |
| 14 | MBD Biotech Provider of drug efficacy and toxicity testing services | $10M | — | 30 | 2015 | Bo Ku CEO | — | — | — |
| 15 | Y-Biologics Developer of antibodies for the treatment of multiple diseases 37Patents top 24%Moat top 35%Innovation top 36%Funding top 40% All 8 signals ▾Patentstop 24% Moattop 35% Innovationtop 36% Fundingtop 40% Marketbottom 44% Fin. healthbottom 39% Globalbottom 37% Techbottom 35% Patents: 166 patents matched (strict assignee match) · 85 filings since 2022 vs 81 in 2017-21 Moat: Editorial + unicorn rating 4/10 · IP moat: 166 patents rank vs industry peers · Fliar Intelligence Index 37/100 | $9M | 10 mo ago | 57 | 2007 | — | Framer SitesReactPriority Hints+4 | 166 patents Therapeutic antibodies and ADCs targeting cancer antigens and immune checkpoints | — |
| 16 | NanoEntek Develops point-of-care instruments for in vitro diagnostics and life science research. | $8M | 130 mo ago | 138 | 2000 | — | GnuboardMySQLPHP+19 | 152 patents Microfluidic particle and cell counting chips for precise fluid analysis | — |
| 17 | Novelty Nobility Developer of therapeutics for eye and cancer diseases | $8M | 76 mo ago | 33 | 2018 | Sang Park Founder & CEO | — | 55 patents Therapeutic antibodies and ADCs targeting c‑Kit, CDCP1, VEGF, HIF‑1α for cancer and mast‑cell diseases | — |
| 18 | ENCell Provider of services for stem cell research for drug development | $8M | 74 mo ago | 104 | 2018 | Jang wook CEO | Microsoft ASP.NETCloudflarejsDelivr+8 | 70 patents Patents concentrated in chemistry & materials | — |
| 19 | Cellivery Peptide drug delivery platform | $6M | 109 mo ago | 100 | 2014 | — | PHPNginxSlick+7 | — | — |
| 20 | Panagene Provider of peptide nucleic acid products for diagnostic and therapeutic use | $5M | 114 mo ago | 71 | 2001 | Sung Kee Kim President & CEO | — | 170 patents Patents concentrated in chemistry & materials | 1 launch |
| 21 | AbTis Provider of technology for antibody-drug conjugation | $4M | 96 mo ago | 24 | 2016 | Sang Jeon Chung Founder & CEO | — | 65 patents Site-specific antibody‑drug conjugate engineering and Fc‑binding linker technologies | — |
| 22 | Cure Biotech Provider of biopolymers | $2M | 45 mo ago | — | 2016 | Kim Young CEO | — | — | — |
| 23 | The Wave Talk Developer of biosensors to detect and monitor micro-organisms | $2M | 74 mo ago | 14 | 2016 | Youngdug Kim Co-Founder & CEO | Wix eCommerceWixSentry+12 | 148 patents Optical and wave‑based sensors for turbidity and fluid property measurement | 1 launch · 1 award |
| 24 | Tomocube Holographic microtomography for cellular microscopy | $2M | 122 mo ago | 46 | 2015 | — | PHPGSAPLiteSpeed+12 | 86 patents AI‑enhanced 3D quantitative phase and refractive‑index tomography for high‑resolution imaging | 1 launch · 1 expansion |
| 25 | Seegene Technologies Developer of molecular diagnostic kits to detect infectious and genetic diseases | $2M | 78 mo ago | — | 2000 | Jong Yoon Chun CEO | Node.jsSalesforceTailwind CSS+14 | 1,257 patents Multiplex nucleic‑acid diagnostic assay design, automation, and data‑driven infectious disease testing | 1 launch · 1 award |
| 26 | Anymedi Provider of platform for medical image upload, 3D modeling, and 3D printing service | $1M | 103 mo ago | 54 | 2016 | Guk Bae Kim CEO | — | 51 patents Neurosurgical navigation guides, personalized surgical guides, and endoscopic simulation training devices. | — |
Top 12 Life Sciences Platforms and Tools companies in South Korea
#1
Public · Seoul, Seoul · founded 2012 · 65 employees$30Mraised▾
ROKIT HEALTHCARE provides 4D bio-printer solutions for tissue regenerative. The company offers its propriety technology for organ regeneration and 3D bio-fabrication technologies for personalized therapy in the areas of skin, cartilage, retina and heart patch regeneration. The company flagship product INVIVO, is a sterilized printer equipped for developing the biomolecules, and polymers to create 3D structures.
- Mar 2026Post IPO$42.1M
- Jul 2020Series C—
- Jan 2019Series B$9.9M
- 2015Grant (prize money)$3M
#2
Public · Seongnam-si, Gyeonggi-do · founded 2000$67.8Mraised▾
Developer of stem cell therapeutics. The company's pluripotent stem cells therapeutics include hESC-RPE (embryonic-derived RPE cells) and SCNT-RPE (somatic cell replication RPE cells) used to treat Stargardt disease and atrophic age-related macular degeneration. The company's adult stem cells therapeutic includes PLX-PAD (placental mesenchymal-like cells) for Intermittent Lameness and Severe limb ischemia, eCASs (enhanced umbilical cord stem cells) for acute stroke and degenerative disc disease, fetal–NPC (Nerve Progenitor Cell) for Parkinson's disease, and adipose-derived mesenchymal stem cells for degenerative lumbar vertebra. The company also aims to develop immune cell therapy to treat Relapsed glioblastoma.
- Jan 2026Post IPO$67.8M
#3
Public · Daejeon, Daejeon · founded 2007 · 57 employees$9Mraised▾
Developer of antibodies for the treatment of multiple diseases. It has designed a proprietary technology to develop the antibody for therapeutic application. The company has secured a set of cDNA libraries and a set of receptor libraries for the selection of the antibody and new target discovery and evaluation. It has also developed a proprietary transient HEK293 system for transfection and protein production. Additionally, the company offers several antibody-related services.
- Aug 2025Post IPO$25.2M
- Nov 2018Series C$33.1M
- Apr 2016Series A$9M
#4
Series C · Seoul, Seoul · founded 2019 · 20 employees$29.3Mraised▾
Developer of human organ model chips for pharmaceutical development. The company develops and produces a 3D cell cultures organ-on-a-chip platform such as the MEPS-X series and MG-X series to develop drug candidates which target Alzheimer's and brain tumors.
- Nov 2024Series C$14.8M
- Jul 2022Series B$8M
- Aug 2021Series A$3.5M
- Aug 2020Series A$2.9M
#5
Public · Seoul, Seoul · founded 2014 · 68 employees$2.4Braised▾
Cellid is involved in developing personalized vaccines for treating cancer and infectious diseases. They have developed a platform, CeliVax, which activates the anti-cancer immune system which allows the immune cells to detect and kill cancer cells. Their pipeline products include BVAC-C is being investigated for cervical, head, and neck cancer, and BVAC-B for gastric cancer. The candidates are in phase II clinical trial.
- 2016Series A—
- 2015Series A—
- 2014Series A—
- 2014Series A—
#6
Series B · Incheon, Incheon · founded 2018 · 63 employees$35.3Mraised▾
Uppthera is a developer of drugs for treating multiple diseases. It has developed new drugs by using PROTAC technology. It provides a protein degradation platform employing a ubiquitin-proteasome system in the body. It consists of two linked protein binding molecules, one capable of engaging an E3 ubiquitin ligase and the other to a target protein meant for degradation. The developed products help in treating metabolic disease and several cancers including hematologic malignancy, and others.
- May 2022Series B$22M
- 2020Series A$11M
- 2019Seed$2.3M
#7
Public · Seoul, Seoul · founded 2007 · 57 employees$30Mraised▾
Curiox is a bioinstrumentation company spun out of the Agency for Science, Technology, and Research (A*STAR) in Singapore. The company has designed wall-less plates and washers to automate miniaturized cell-based assays. This novel DropArray technology can be miniaturized down to 5ul with minimal changes to the customer workflow. Its products include DropArray Microplate, HT200 Washing Station, and LT210 Washing Station.
- Mar 2022Series C$15M
- Oct 2019Series B$15M
- Oct 2009Series B—
- Dec 2007Series A—
#8
Series C · Seoul, Seoul · founded 2013 · 9 employees$27.5Mraised▾
Developer of drug delivery technology and biosensor technology. The DegradaBALLis a drug delivery technology for the development of gene therapy, cancer immunotherapy, antibody therapy, and synthetic drugs. The PANGO technology is the next-generation drug screening technology that allows the rapid screening of antiviral drugs from the drug candidate library.
- Apr 2021Series C$13.9M
- Dec 2018Series B$10.3M
- Mar 2018Series A$3.3M
#9
Series B · Seoul, Seoul · founded 2012 · 22 employees$27Mraised▾
Provider of induced pluripotent stem cell (iPSC)-derived cells and organoids. It manufactures iPSC-derived cardiomyocytes, neurons, and hepatocytes for drug response, 3D printing, and electrophysiological experiments. The company also produces iPSC-derived cardiac and heart organoids, offering services in cardiac safety evaluation, custom cell production, and iPSC reprogramming. It develops and patents new drug candidates using hiPSC-based technologies and disease models. These services support drug development, reducing reliance on animal testing.
- Apr 2021Series B$15.6M
- 2019Series B—
#10
Series B · Suwon-si, Gyeonggi-do · founded 2001 · 11 employees$17.3Mraised▾
Developer of biomaterials based on recombinant protein production technology. The platform is manufacturing and developing protein products that can be used for medicine, food, and the cosmetic industry. The platform has developed the proprietary technology rProtein Manufacturing AD-Pure System for the production of recombinant protein.
- Nov 2021Series B$17.3M
- 2018Seed—
#11
Acquired · Seongnam-si, Gyeonggi-do · founded 2015 · 12 employees$10.6Mraised▾
Provider of molecular spectroscopy systems for early-stage skin cancer detection. It has developed a non-invasive diagnostic tool based on laser spectroscopy and statistical algorithm for early-stage skin cancer detection. This in-vivo laser technology works by analyzing the chemical composition of the tissues.
- Aug 2021Series A$8M
- Nov 2016Seed$2.6M
#12
Series B · Seoul, Seoul · founded 2016 · 27 employees$11.6Mraised▾
“The earlier you discover, the better you recover†GENECAST is biotechnology company specialized in cancer diagnosis using liquid biopsy. ADPS, our proprietary technology which has maximum detection sensitivity of 0.0001%, can recognize cancer mutation genes quickly and accurately among other conventional liquid biopsy technologies. FACE CANCER with ADPS
Funding & investor landscape
Notable founders
How research on Bioinformatics is moving in South Korea
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,344 South Korea-affiliated papers.
- Ministry of Education187
- Seoul National University134
- Yonsei University85
- Ministry of Agriculture72
- Korea University65
- Gene3→61
- Genome5→47
- Identification (biology)3→24
- CRISPR3→16
- Transcription factor1→13
- Gene2→43
- Cancer2→30
- microRNA1→9
- Cancer therapy1→6
- Disease1→26
- Diabetes mellitus1→5
Where bioinformatics is researched across South Korea
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing bioinformatics patents in South Korea
South Korea bioinformatics patent filing is cooling — 20 filings from 6 assignees (2016–2025), led by Korea Basic Science INST, Pharmcadd, Deargen; annual filings 2→1.
- Korea Basic Science INST10
- Pharmcadd7
- Deargen3
- Samsung3
- Istech2
- Gardner Steve1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.